Westlake Village biotech company MannKind announced a 118 percent increase in revenue for its third quarter and cut net losses more than 26 percent, sending shares up more than 5 percent in midday trading Nov. 1. Afrezza revenues continued their slow and steady climb. Sales of the inhalable insulin product rose to $4.4 million for…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
